Who We are
Burning Rock is a biotechnology company that focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Our expertise in novel NGS technology, strategic partnerships with other leading biotechnology companies in the industry, and our world-leading technologies uniquely position us to lead the charge towards individualized patient care.
We are working to establish a global network of CLIA/CAP labs to simplify the process of running concurrent trials in different countries and improving data comparability across regions. In combination with our IVD kit capability and cGMP manufacturing, this global perspective lends itself toward standardization, collaboration, and concurrence across sites. Burning Rock Guangzhou lab has successfully obtained the ISO13485 certification, which is a comprehensive certification of the Company’s Quality Management System for the design and development, production, and sales of in vitro diagnostic reagents, software and sample preparation system. We currently operate 3 labs. A CLIA / CAP / ISO 15189 lab in Guangzhou with NGS and IHC capability, a CLIA/CAP lab in Irvine, CA with NGS, IHC, and R&D capability, and a lab in Shanghai with R&D and NGS capability.
Burning Rock offers a variety of DNA and RNA NGS panels across numerous cancer types including Breast, GI, Lung, Prostate, Lymphoma, Thyroid, and Pan cancers. We offer our partners true flexibility in testing with the capability of developing custom assays and utilizing multiple sample sources including plasma, FFPE, and white buffy coat.